NEW OPPORTUNITIES TO IMPROVE THE QUALITY AND DURATION OF LIFE IN PATIENTS WITH STABLE ISCHEMIC HEART DISEASE

Download full text PDF
Issue: 
1
Year: 
2017

Professor R. Oganov, MD, Academician of the Russian Academy of Sciences National Research Center for Preventive Medicine, Moscow

The paper discusses the issues of treating stable coronary heart disease: such as the signs and etiology of the disease, predictors of poor prognosis, international guidelines for treatment. The paper considers the principles of optimal therapy that includes medications to alleviate symptoms, to relieve pain, and to prevent complications. The mechanisms of action of the antianginal drug nicorandil are given. It is concluded that it is appropriate to more frequently use nicorandil in the therapy of various clinical manifestations of coronary heart disease.
Keywords: 
cardiology
coronary heart disease
optimal therapy
nicorandil

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. FOX K., Garcia M., Ardissino D. et al. Guidelines on the management of stable angina pectoris // Eur. Heart J. – 2006; 27: 1341–81.
  2. Montalescot G., Sechtem U., Aschenbach S. et al. 2013 ESC Guidelines on the management of stable coronary disease // Eur. Heart J. – 2013; 34: 2949–3003.
  3. Marzilli M., Merz C., Boden W. et al. Obstructive coronary atherosclerosis and ischemic heart disease: an elusive link! // J. Am. Coll. Cardiol. – 2012; 60: 951–6.
  4. Ford E., Ajani U., Croft J. et al. Expending the disease in the US deaths from Coronary Disease 1980–2000 // N. Engl. J. Med. – 2007; 256: 2388–98.
  5. Karpov Ju.A. Aktivator kalievyh kanalov nikorandil: novye vozmozhnosti terapii ishemicheskoj bolezni serdtsa // Atmosfera. Novosti kardiologii. – 2012; 3: 29–33.
  6. Giljarevskij C.R., Rezvan V.V., Kuz'mina I.M. i dr. Sovremennye podhody k protivoishemicheskoj terapii bol'nyh so stabil'nym techeniem ishemicheskoj bolezni serdtsa // Med. alfavit. – 2013; 2: 2–7.
  7. Bulahova E.Ju., Korennova O.Ju., Kondrasheva M.N. i dr. Klinicheskie preimuschestva terapii nikorandilom v sravnenii s izosorbid-5-mononitratom u bol'nyh IBS // Serdtse. – 2013; 2 (70): 83–7.
  8. IONA Study Group. Effect of nicorandil on coronary events in pa- tients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial // Lancet. – 2002; 359: 1269–75.
  9. Horinaka S., Yabe A, Yadi H. et al. Effects of nicorandil on cardiovascular events in patients with Coronary Artery Disease (JCAD) study // Circ. J. – 2010; 74: 503–9.
  10. Sakata Y., Nakatani D., Shimiz M. et al. Oral treatment with nicorandil at discharge is associated with reduced mortality after acute myocardial infarction // J. Cardiol. – 2012; 59: 14–21.
  11. Yang J., Zhang J., Cui W. et al. Cardioprotective effects of single oral dose of nicorandil before selective percutaneous coronary intervention // Anadolu Kardiyol. Derg. – 2015; 15: 125–31.
  12. Xia F., Wang Z., Zhou Y. et al. Cerebral protective effect of nicorandil premedication on patients undergoing liver transplantation // Hepatobiliary Pancreat. Dis. Int. – 2012; 11: 132–6.
  13. Rumjantseva S.A., Oganov R.G, Silina E.V. i dr. Serdechnososudistaja patologija pri ostrom insul'te (nekotorye aspekty rasprostranennosti, profilaktiki i terapii) // Kardiovask. ter. i profilakt. – 2014; 4: 47–53.